To date, LPCAT1 over-expression has been reported in hepatocellular carcinoma [34], colorectal adenocarcinoma [35], prostate cancer [36–38] and oral squamous cell carcinoma [12, 39], and has been identified as a contributor to cancer progression, metastasis, and recurrence. Here, LPCAT1 is linked to prostate carcinoma.